Vincristine (Sulphate)

Also known as: Leurocristine sulphate

Drug #754

Vincristine (Sulphate) is antineoplastic (anticancer) drug. Vincristine (Sulphate) is alkaloid derivative of Vinca rosea, the periwinkle plant. Structurally Vincristine (Sulphate) is a complexed compound and differ from vinblastine only in having an aldehyde moiety. Vinblastine is an alkaloid extracted from the periwinkle plant. Vincristine (Sulphate) is a parenteral, cell cycle-phase specific antineoplastic agent used in the management of breast carcinoma, bladder carcinoma, Hodgkin's disease, melanoma, and testicular carcinoma. Vincristine is similar to vinblastine in action, but their toxicities differ significantly. Vincristine was approved by the FDA in 1961. Vincristine (Sulphate) is used in combination of different anticancer drugs to obtain best therapeutic effect and minimize side effects or toxicity.

← Previous drug Next drug →

Primary Characteristics

Vincristine (Sulphate) is also known as Leurocristine sulphate.

It is of Natural origin and belongs to Alkaloid.

It is classified in Antineoplastic Agent, Plant Derivative pharmacological group. It is also classified under Mitotic Inhibitors .

Molecular Weight: 923 · pK_a: 5.0, 7.4 · Solubility in Water: 1 in 2 · Solubility in Alcohol: 1 in 600 · Non-proprietary name: Vincristine (Sulphate).

Molecular structure of Vincristine (Sulphate)

Pharmacokinetics

Absorption: Vincristine (Sulphate) has an oral bioavailability is 5.5% (±4.5%), pre-systemic (first-pass) metabolism accounts for 0.5% (±0.5%).

Distribution: Vincristine (Sulphate) has a volume of distribution is 8.4 l/kg. plasma protein binding is low.

Elimination: it is metabolised via Hepatic, plasma half-life is 85 hr, renal excretion is 12 %.

Indications

Vincristine (Sulphate) is primarily indicated in conditions like Acute leukemia, Breast cancer, Hodgkin's disease, Leukaemia, Lymphomas, Neuroblastoma, Non-hodgkin's lymphoma, Rhabdomyosarcoma, Solid tumor, Wilms tumor.

Contraindications

Vincristine (Sulphate) is contraindicated in conditions like Bronchospasm, Jaundice, Marie tooth syndrome.

Dosage

Vincristine (Sulphate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.45 mg/sq.meter	1.45 mg/sq.meter	—	IV	Once in a Week
Paediatric Dosage (20kg)
1.5 mg/sq.meter	1.5 mg/sq.meter	—	Intra Venous	Per Week for 3-6 Weeks, As Required
Neonatal Dosage (3kg)
0.05 mg/kg	0.05 mg/kg	—	Intravenous	Initial once weekly then as required

Drug Interactions

Unknown3 interactions

3 interactions

Minor1 interaction

Moderate2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Vincristine (Sulphate) in overdosage may give rise to further complications which include GI symptoms, Neurotoxicity .

The signs and symptoms that are produced after acute overdosage of Vincristine (Sulphate) are Myelosuppression .

Vincristine (Sulphate) is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Constipation , Diarrhea, Dizziness, Fever, Headache, Vomiting , Weight loss.

Warnings / Precautions

Vincristine is not recommended for use in pregnant or nursing women. Contraceptive measures are recommended for use in men or women when taking this drug. It can lower body's ability to fight an infection, consult the doctor if any sign of an infection such as fever, sore throat, rash or chills appear. Do not have immunizations or vaccinations without consent of doctor and avoid contact with people who have recently received oral polio vaccine.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

1 mg 2 mg

Storage Conditions

Vincristine (Sulphate) should be stored Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Vincristine (Sulphate) in Pakistan:

Al-Habib Atco Pharmedic Swiss Pharma Turner